MILLENNIUM PHARMACEUTICALS INC 3
3 · Calithera Biosciences, Inc. · Filed Apr 21, 2022
Insider Transaction Report
Form 3
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Holdings
- (indirect: See Explanation of Responses)
Series A Convertible Preferred Stock
Exercise: $2.04From: 2021-10-18→ Common Stock (1,000,000 underlying)
Footnotes (3)
- [F1]The Series A preferred stock has no expiration date.
- [F2]The Series A preferred stock is initially convertible into 17,156,863 shares of common stock of Calithera Biosciences, Inc. ("Calithera") at a conversion price per share of $2.04, subject to price-based anti-dilution adjustments which, if triggered, would result in additional shares of Calithera common stock being issued upon conversion of the Series A preferred stock.
- [F3]These shares are owned directly by Millennium Pharmaceuticals, Inc.. which is a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.